| Customization: | Available |
|---|---|
| Powder: | Yes |
| Customized: | Non-Customized |
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
Macitentan is a non-chiral sulphadiazine derivative. In vitro studies have shown that it is an oral active antagonist of endothelin ETA and ETB receptor, which can block endothelin-induced vasoconstriction in trachea and aorta. Developed by Swiss company Actelion Pharmaceuticals and first marketed in the United States with FDA approval on October 18, 2013, it is mainly used to treat pulmonary hypertension (PAH) and its product name is Opsumit. Compared with other drugs for pahs, masititan can significantly reduce the morbidity and mortality of pahs patients mainly by slowing the progression of disease.
1.COA/MSDS/ROS/MOA Available.
2.Any inquiries will be replied within 12 hours.
3. Dedication to quality, supply & service.
4.Strictly on selecting raw materials.
5.Reasonable & competitive price, fast lead time.
6.Faster delivery:Sample order in stock and one week for bulk production.
7.We have strong cooperation with DHL, TNT, UPS, FEDEX, EMS. Or you also can choose your own shipping forwarder.
8.Timely after-service resolves your worry for internation trade.
9.Payment:
){kind=link}